October 27, 2016 09:53 AM EDTUpdated 10:18 AM

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

Shehla Shakoor

Managing Director

GlaxoSmithKline didn’t just kill losmapimod on Wednesday. The pharma giant was also forced to dump a late-stage HIV drug acquired from Bristol-Myers late last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

Shehla Shakoor

Managing Director

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

GSK dumps a late-stage HIV drug; MIT of­fers sup­port for tech start-ups; Ra Phar­ma clos­es flat af­ter $92M IPO

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market